Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Published byAlžběta Matoušková Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion."— Presentation transcript:

1 Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Ldlr−/− mice were fed the Western diet for 12 weeks and then injected intravenously with Col IV NPs containing scrambled peptide (Scrm) or Ac2-26 once per week for 5 weeks, with the mice remaining on the diet. (A and B) Representative whole-mount (A) or cross-sectioned specimens (B) of BCA lesions were visualized en bloc or in cross section. Scale bar, 100 μm. (C to F) Cross sections were quantified for lesion area (C), necrotic area (D), ICAM immunostaining (E), and superoxide (DHE fluorescence) (F). Data are for individual mice, with means shown as horizontal lines (n = 8 to 10 separate mice, two sections per mouse). *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test. Gabrielle Fredman et al., Sci Transl Med 2015;7:275ra20 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion."

Similar presentations

Assessment of Unstable Atherosclerosis in Mice

Assessment of Unstable Atherosclerosis in Mice
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Volume 15, Issue 4, Pages (April 2012)

Volume 15, Issue 4, Pages (April 2012)
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Volume 15, Issue 3, Pages (March 2012)

Volume 15, Issue 3, Pages (March 2012)
Fig. 1. NASH and fibrosis develop late in mice fed an HFD.

Fig. 1. NASH and fibrosis develop late in mice fed an HFD.
Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.
Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.
Depletion of Drosha in the endothelium in mice results in embryonic developmental vascular abnormalities similar to HHT. Depletion of Drosha in the endothelium.

Depletion of Drosha in the endothelium in mice results in embryonic developmental vascular abnormalities similar to HHT. Depletion of Drosha in the endothelium.
Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.
Volume 10, Issue 1, Pages (July 2009)

Volume 10, Issue 1, Pages (July 2009)
Volume 15, Issue 3, Pages (March 2012)

Volume 15, Issue 3, Pages (March 2012)
Cytosolic entry of Lm required for CD8α+ DC recruitment.

Cytosolic entry of Lm required for CD8α+ DC recruitment.
Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
Fig. 5 Nec-1 therapy decreases atherosclerotic lesion progression and markers of instability in Apoe−/− mice. Nec-1 therapy decreases atherosclerotic lesion.

Fig. 5 Nec-1 therapy decreases atherosclerotic lesion progression and markers of instability in Apoe−/− mice. Nec-1 therapy decreases atherosclerotic lesion.
Fig. 1. PolySTAT synthesis and characterization.

Fig. 1. PolySTAT synthesis and characterization.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Similar presentations

Ads by Google